Serum interleukin-6 level and its association with pulmonary involvement in progressive systemic sclerosis; a...

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Primary Systemic Sclerosis (PSS) is a connective tissue disease causing excessive collagen deposition.
• Interstitial lung disease (ILD) is a common complication of PSS, potentially influenced by cytokines.
• Interleukin-6 (IL-6) is a cytokine implicated in various inflammatory processes.

Purpose of the Study:

• To investigate the association between serum IL-6 levels and pulmonary involvement in patients with PSS.
• To evaluate IL-6 as a potential biomarker or therapeutic target for PSS-ILD.

Main Methods:

• A case-control study involving 60 PSS patients (30 with pulmonary involvement, 30 without).
• Serum IL-6 levels, C-reactive protein (CRP), and pulmonary artery pressure (PAP) were measured.
• Disease duration, activity, chest imaging (CXR, HRCT), and echocardiography (EF) were assessed.

Main Results:

• No significant difference in overall serum IL-6 levels between PSS patients with and without pulmonary involvement.
• Significantly higher IL-6 levels were observed in male PSS patients with pulmonary involvement compared to male controls.
• Patients with pulmonary involvement exhibited longer disease duration, higher CRP and PAP, and lower ejection fraction (EF).

Conclusions:

• Serum IL-6 levels do not appear to be directly associated with pulmonary involvement in PSS.
• IL-6 may not serve as a reliable biomarker or therapeutic target for PSS-related lung disease based on this study.
• Further research may be needed to explore other cytokines or factors in PSS-ILD pathogenesis.